372 related articles for article (PubMed ID: 31592328)
1. Randomised prospective trial to assess the clinical utility of multianalyte assay panel with complement activation products for the diagnosis of SLE.
Wallace DJ; Alexander RV; O'Malley T; Khosroshahi A; Hojjati M; Loupasakis K; Alper J; Sherrer Y; Fondal M; Kataria R; Powell T; Ibarra C; Narain S; Massarotti E; Weinstein A; Dervieux T
Lupus Sci Med; 2019; 6(1):e000349. PubMed ID: 31592328
[TBL] [Abstract][Full Text] [Related]
2. Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology-Classified Systemic Lupus Erythematosus.
Ramsey-Goldman R; Alexander RV; Massarotti EM; Wallace DJ; Narain S; Arriens C; Collins CE; Saxena A; Putterman C; Kalunian KC; O'Malley T; Dervieux T; Weinstein A
Arthritis Rheumatol; 2020 Jan; 72(1):78-88. PubMed ID: 31469249
[TBL] [Abstract][Full Text] [Related]
3. Complement activation products vs standard ANA testing: Treatment outcomes, diagnosis, and economic impact (CAPSTONE) in systemic lupus erythematosus.
O'Malley T; Xie F; Su Y; Clinton C; Zack DJ; Haechung C; Grabner M; Curtis JR
J Manag Care Spec Pharm; 2022 Sep; 28(9):1021-1032. PubMed ID: 35775579
[No Abstract] [Full Text] [Related]
4. Systemic lupus erythematosus and primary fibromyalgia can be distinguished by testing for cell-bound complement activation products.
Wallace DJ; Silverman SL; Conklin J; Barken D; Dervieux T
Lupus Sci Med; 2016; 3(1):e000127. PubMed ID: 26870391
[TBL] [Abstract][Full Text] [Related]
5. Cell-bound complement activation products (CB-CAPs) have high sensitivity and specificity in pediatric-onset systemic lupus erythematosus and correlate with disease activity.
Hui-Yuen JS; Gartshteyn Y; Ma M; O'Malley T; Conklin J; Eichenfield AH; Imundo LF; Dervieux T; Askanase AD
Lupus; 2018 Dec; 27(14):2262-2268. PubMed ID: 30376789
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the Economic Benefit of Earlier Systemic Lupus Erythematosus (SLE) Diagnosis Using a Multivariate Assay Panel (MAP).
Clarke AE; Weinstein A; Piscitello A; Heer A; Chandra T; Doshi S; Wegener J; Goss TF; Powell T
ACR Open Rheumatol; 2020 Nov; 2(11):629-639. PubMed ID: 33044050
[TBL] [Abstract][Full Text] [Related]
7. The Avise Lupus Test and Cell-bound Complement Activation Products Aid the Diagnosis of Systemic Lupus Erythematosus.
Mossell J; Goldman JA; Barken D; Alexander RV
Open Rheumatol J; 2016; 10():71-80. PubMed ID: 27867431
[TBL] [Abstract][Full Text] [Related]
8. A Multianalyte Assay Panel With Cell-Bound Complement Activation Products Predicts Transition of Probable Lupus to American College of Rheumatology-Classified Lupus.
Ramsey-Goldman R; Alexander RV; Conklin J; Arriens C; Narain S; Massarotti EM; Wallace DJ; Collins CE; Saxena A; Putterman C; Brady K; Kalunian KC; Weinstein A
ACR Open Rheumatol; 2021 Feb; 3(2):116-123. PubMed ID: 33538130
[TBL] [Abstract][Full Text] [Related]
9. A multianalyte assay panel with cell-bound complement activation products demonstrates clinical utility in systemic lupus erythematosus.
Alexander RV; Rey DS; Conklin J; Domingues V; Ahmed M; Qureshi J; Weinstein A
Lupus Sci Med; 2021 Jul; 8(1):. PubMed ID: 34253650
[TBL] [Abstract][Full Text] [Related]
10. Cell-bound complement activation products associate with lupus severity in SLE.
Arriens C; Alexander RV; Narain S; Saxena A; Collins CE; Wallace DJ; Massarotti E; Conklin J; Kalunian KC; Putterman C; Ramsey-Goldman R; Buyon JP; Askanase A; Furie RA; James JA; Bello GA; Manzi S; Ahearn J; O'Malley T; Weinstein A; Dervieux T
Lupus Sci Med; 2020 Apr; 7(1):. PubMed ID: 32371480
[TBL] [Abstract][Full Text] [Related]
11. Probable systemic lupus erythematosus with cell-bound complement activation products (CB-CAPS).
Lamichhane D; Weinstein A
Lupus; 2016 Aug; 25(9):1050-3. PubMed ID: 26911153
[TBL] [Abstract][Full Text] [Related]
12. A Review of Complement Activation in SLE.
Weinstein A; Alexander RV; Zack DJ
Curr Rheumatol Rep; 2021 Feb; 23(3):16. PubMed ID: 33569681
[TBL] [Abstract][Full Text] [Related]
13. Cell-bound complement activation products in SLE.
Ramsey-Goldman R; Li J; Dervieux T; Alexander RV
Lupus Sci Med; 2017; 4(1):e000236. PubMed ID: 29214038
[TBL] [Abstract][Full Text] [Related]
14. Reduction in erythrocyte-bound complement activation products and titres of anti-C1q antibodies associate with clinical improvement in systemic lupus erythematosus.
Buyon J; Furie R; Putterman C; Ramsey-Goldman R; Kalunian K; Barken D; Conklin J; Dervieux T
Lupus Sci Med; 2016; 3(1):e000165. PubMed ID: 27752336
[TBL] [Abstract][Full Text] [Related]
15. Cell-bound complement activation products as lupus biomarkers: diagnosis, monitoring and stratification.
Ahearn JM; Liu CC; Manzi S
Expert Rev Clin Immunol; 2017 Dec; 13(12):1133-1142. PubMed ID: 29025354
[TBL] [Abstract][Full Text] [Related]
16. Practice patterns in longitudinal lupus care provision: patient and physician perspectives.
Kugasia A; Sehgal N; Dollear M; Sequeira W; Block JA; Jolly M
Lupus; 2017 Dec; 26(14):1556-1561. PubMed ID: 28659044
[TBL] [Abstract][Full Text] [Related]
17. Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus.
Kalunian KC; Chatham WW; Massarotti EM; Reyes-Thomas J; Harris C; Furie RA; Chitkara P; Putterman C; Gross RL; Somers EC; Kirou KA; Ramsey-Goldman R; Hsieh C; Buyon JP; Dervieux T; Weinstein A
Arthritis Rheum; 2012 Dec; 64(12):4040-7. PubMed ID: 22932861
[TBL] [Abstract][Full Text] [Related]
18. Validation of a multi-analyte panel with cell-bound complement activation products for systemic lupus erythematosus.
Dervieux T; Conklin J; Ligayon JA; Wolover L; O'Malley T; Alexander RV; Weinstein A; Ibarra CA
J Immunol Methods; 2017 Jul; 446():54-59. PubMed ID: 28389175
[TBL] [Abstract][Full Text] [Related]
19. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.
Teng YKO; Bruce IN; Diamond B; Furie RA; van Vollenhoven RF; Gordon D; Groark J; Henderson RB; Oldham M; Tak PP
BMJ Open; 2019 Mar; 9(3):e025687. PubMed ID: 30898822
[TBL] [Abstract][Full Text] [Related]
20. Are anti-nucleosome antibodies a better diagnostic marker than anti-dsDNA antibodies for systemic lupus erythematosus? A systematic review and a study of metanalysis.
Bizzaro N; Villalta D; Giavarina D; Tozzoli R
Autoimmun Rev; 2012 Dec; 12(2):97-106. PubMed ID: 22810055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
